UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study

American journal of kidney diseases, 2018-11, Vol.72 (5), p.653-661

2018

Volltextzugriff (PDF)

Tunneling-nanotube development in astrocytes depends on p53 activation

Cell death and differentiation, 2011-04, Vol.18 (4), p.732-742

2011

Volltextzugriff (PDF)

EGFR signaling pathway as therapeutic target in human cancers

Seminars in cancer biology, 2022-10, Vol.85, p.253-275

2022

Volltextzugriff (PDF)

Targeting the EGFR signaling pathway in cancer therapy

Expert opinion on therapeutic targets, 2012-01, Vol.16 (1), p.15-31

2012

Volltextzugriff (PDF)

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

American journal of kidney diseases, 2020-01, Vol.75 (1), p.84-104

2020

Volltextzugriff (PDF)

Threshold-controlled ubiquitination of the EGFR directs receptor fate

The EMBO journal, 2013-07, Vol.32 (15), p.2140-2157

2013

Volltextzugriff (PDF)

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib

Lung cancer (Amsterdam, Netherlands), 2017-06, Vol.108, p.228

2017

Volltextzugriff (PDF)

Pyrimidine derivatives as EGFR tyrosine kinase inhibitors in non‐small‐cell lung cancer: A comprehensive review

Chemical biology & drug design, 2022-10, Vol.100 (4), p.599-621

2022

Volltextzugriff (PDF)

Germline EGFR c.2527G > A (p.V843I) variant and familial lung cancer

Lung cancer (Amsterdam, Netherlands), 2023-07, Vol.181, p.107247, Article 107247

2023

Volltextzugriff (PDF)

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Journal of thoracic oncology, 2021-06, Vol.16 (6), p.1030-1041

2021

Volltextzugriff (PDF)

Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial

European journal of cancer (1990), 2023-07, Vol.188, p.8-19

2023

Volltextzugriff (PDF)

Unveiling resistance mechanisms to EGFR inhibitors in cholangiocarcinoma

Oncotarget, 2018-12, Vol.9 (99), p.37274-37275

2018

Volltextzugriff (PDF)

Abstract 2332 Small GTPase Arl4A attenuates EGFR degradation by binding to the ESCRT-II-complex

The Journal of biological chemistry, 2024-03, Vol.300 (3), p.106716, Article 106716

2024

Volltextzugriff (PDF)

Abstract 2245 Discovery and functional characterization of potential biomarkers for wild-type EGFR lung adenocarcinoma via super-SILAC-based quantitative tissue proteomic analysis

The Journal of biological chemistry, 2024-03, Vol.300 (3), p.106659, Article 106659

2024

Volltextzugriff (PDF)

Leptomeningeal Metastatic L858R EGFR-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib

OncoTargets and therapy, 2022-06, Vol.15, p.659-667

2022

Volltextzugriff (PDF)

EGFR Inhibition by Erlotinib Rescues Desmosome Ultrastructure and Keratin Anchorage and Protects against Pemphigus Vulgaris IgG–Induced Acantholysis in Human Epidermis

Journal of investigative dermatology, 2024-04

2024

Volltextzugriff (PDF)

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

Journal of thoracic oncology, 2020-05, Vol.15 (5), p.803-815

2020

Volltextzugriff (PDF)

HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer

The oncologist (Dayton, Ohio), 2019-10, Vol.24 (10), p.1395-1402

2019

Volltextzugriff (PDF)

Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)

European journal of medicinal chemistry, 2020-03, Vol.189, p.112061-112061, Article 112061

2020

Volltextzugriff (PDF)

A perspective on anti-EGFR therapies targeting triple-negative breast cancer

American journal of cancer research, 2016-01, Vol.6 (8), p.1609-1623

2016

Volltextzugriff (PDF)

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET

The Journal of biological chemistry, 2021-01, Vol.296, p.100641-100641, Article 100641

2021

Volltextzugriff (PDF)

Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer

Future oncology (London, England), 2021-03, Vol.17 (8), p.965-977

2021

Volltextzugriff (PDF)

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations

International journal of cancer, 2019-06, Vol.144 (11), p.2887-2896

2019

Volltextzugriff (PDF)

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics

Frontiers in cell and developmental biology, 2023-09, Vol.11, p.1176657-1176657

2023

Volltextzugriff (PDF)

1 – 25 von 21.389

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19.122)
Mit Volltextzugriff
(19.242)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(18.726)
Life Sciences & Biomedicine
(18.116)
Egfr
(12.397)
Humans
(12.080)
Oncology
(8.637)
Female
(5.522)
Mutation
(4.615)
Male
(4.450)
Middle Aged
(3.663)
Lung Cancer
(3.580)
Animals
(3.379)
Aged
(3.329)
Epidermal Growth Factor Receptors
(3.209)
Epidermal Growth Factor
(3.173)
Tumors
(3.159)
Cell Line, Tumor
(2.914)
Lung Neoplasms - Genetics
(2.780)
Adult
(2.629)
Biochemistry & Molecular Biology
(2.617)
Lung Neoplasms - Drug Therapy
(2.577)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(13.121)
Elektronische Zeitschriftenbibliothek - Freely accessible e-journals
(11.693)
IngentaConnect
(10.640)
IngentaConnect Journals
(6.095)
Journals@Ovid Full Text
(6.072)
Elsevier ScienceDirect Journals Complete
(4.598)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(3.508)
SpringerLink Journals - AutoHoldings
(2.848)
Wiley Online Library - AutoHoldings Journals
(2.306)
Publisher or Other Site
(2.169)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(1.641)
Taylor & Francis Journals
(1.551)
Wiley Online Library Full Collection 2018
(1.498)
Taylor & Francis Current Content Access
(1.222)
Taylor & Francis:Master (3349 titles)
(937)
Nexis Uni
(563)
Nature International Weekly Journal of Science
(495)
Oxford Journals
(395)
SAGE Journals
(376)
Ebook Central Perpetual and DDA
(347)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Lung Cancer
(593)
Oncotarget
(452)
Frontiers In Oncology
(369)
Journal Of Thoracic Oncology
(335)
Cancers
(318)
International Journal Of Molecular Sciences
(269)
Anticancer Research
(244)
Bmc Cancer
(207)
The Journal Of Biological Chemistry
(189)
American Journal Of Kidney Diseases
(188)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study

Tunneling-nanotube development in astrocytes depends on p53 activation

EGFR signaling pathway as therapeutic target in human cancers

Targeting the EGFR signaling pathway in cancer therapy

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

Threshold-controlled ubiquitination of the EGFR directs receptor fate

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib

Pyrimidine derivatives as EGFR tyrosine kinase inhibitors in non‐small‐cell lung cancer: A comprehensive review

Germline EGFR c.2527G > A (p.V843I) variant and familial lung cancer

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial

Unveiling resistance mechanisms to EGFR inhibitors in cholangiocarcinoma

Abstract 2332 Small GTPase Arl4A attenuates EGFR degradation by binding to the ESCRT-II-complex

Abstract 2245 Discovery and functional characterization of potential biomarkers for wild-type EGFR lung adenocarcinoma via super-SILAC-based quantitative tissue proteomic analysis

Leptomeningeal Metastatic L858R EGFR-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib

EGFR Inhibition by Erlotinib Rescues Desmosome Ultrastructure and Keratin Anchorage and Protects against Pemphigus Vulgaris IgG–Induced Acantholysis in Human Epidermis

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer

Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)

Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development

A perspective on anti-EGFR therapies targeting triple-negative breast cancer

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET

Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics

Aktive Filter

Suchergebnisse filtern